Background. During the winter of [2002][2003], the Israeli health authorities launched a campaign to vaccinate first responders against smallpox.
Inoculation with vaccinia virus has proved to be very effective for immunization against smallpox. Until recently, smallpox was considered to have only historical relevance, because a multinational comprehensive eradication campaign led to the eradication of naturally occurring smallpox during the late 1970s [1, 2] . As a result of the eradication of smallpox, routine vaccination with vaccinia virus ceased. Thus, more than one-half of today's world population has never been vaccinated, and it is not known whether individuals who were vaccinated several decades ago are still protected against smallpox [3] . The current susceptibility of the general population to variola and the suspicion that variola virus could be possessed by rogue states or terrorist groups led to serious concern that the virus could be used as a bioterror agent. Therefore, health authorities in Israel decided to vaccinate specific health-care groups, to increase the preparedness of the nation in the event that such a threat materializes [4] . The target population of this program was limited to individuals who had been previously vaccinated, to minimize the probability of severe vaccinerelated adverse events [3] . This vaccination campaign began in Israel in September 2002, and, as of January 2003, ∼17,000 doses had been administered [4] . During the eradication campaign in Israel, the vaccine was routinely given at 1 year of age and at 9-10 years of age. An additional dose was given at 18-19 years of age to new recruits of the Israel Defense Force (IDF). Vaccination of the general population in Israel ceased in 1979.
The vaccine available in Israel is prepared by inoculation of embryonated chicken eggs with the Lister strain of vaccinia virus [5] . The current vaccination program has provided an opportunity to address several important questions related to the rate and correlates of clinical and immunological responses of preimmunized adults after revaccination with vaccinia virus.
PARTICIPANTS, MATERIALS, AND METHODS
Vaccine. The smallpox vaccine used was manufactured by the Central Laboratories of the Israeli Ministry of Health (IMH). As had been done in the past, the vaccine was produced by inoculation of embryonated chicken eggs with the Lister strain of vaccinia virus. After an incubation period, the virus was harvested from the chorioalantoic membranes of the chicken embryos. Each vaccine vial contained a suspension of ∼10 7 pock-forming units (pfu)/mL vaccinia virus.
Study design and participants. The study was designed as an open-label study and followed the IDF Medical Corps Human Experimentation Guidelines. The vaccine was administered during a vaccination campaign targeting first responders in the IDF. Previously vaccinated participants (verified by date of birth, date of recruitment to the IDF, or appropriate scar) who did not meet the exclusion criteria were vaccinated. Exclusion criteria for receiving the vaccine included the following: (1) current or past history of eczema; (2) current active dermatitis, other inflammatory skin diseases, or widespread burns; (3) any known state of immunosuppression or treatment with immunosuppressive drugs; (4) household contact with any of the above; (5) life-threatening allergy to eggs; and (6) known pregnancy. Participants were asked to provide written, informed consent agreeing to clinical follow-up and to donation of serum samples for antibody analysis. A control group with similar demographic parameters (age, sex, and country of origin) was used to evaluate the rates of selected clinical symptoms in unvaccinated participants during the same period. The participants in this group were not vaccinated because of refusal or exclusion. The exclusion criteria for participants in the control group included evidence of dermatitis, minor medical findings of no impact on the measured parameters, and the medical status of family members.
A total of 159 vaccinees and 48 control subjects were followed. Twenty-eight percent of the subjects were women. The mean age of subjects was 33.5 years (median, 31.4 years; range, 24.0-52.5 years). The time since last vaccination ranged between 6.4 and 33.8 years.
The vaccinees were inoculated by the application of 20 mL of the vaccine suspension (10 7 pfu/mL) on the skin overlying the deltoid muscle. A standard 23-gauge disposable syringe needle (Becton Dickinson) was then used to introduce the vaccine intradermally by 15 brisk punctures in a 2-3-mm cluster. The vaccination site was then covered with semipermeable adhesive dressing. Clinical reactions in the vaccinees were actively monitored 3 times during the study via clinical questionnaires and interviews on days 3-4, 7-9, and 14-18 after vaccination. Serum samples were collected before vaccination and on days 14-18. Additional serum samples were collected from a subsample of the vaccinees ∼1 month after vaccination.
Evaluation of successful vaccination. The primary end point for the evaluation of vaccination was that set by the IMH and was based on criteria that had been used in Israel during the eradication campaign. A successful vaccination (hereafter, "clinical take") was defined as the presence of a vesicle, pustule, ulcer, or scab 7-9 days after vaccination. A secondary end point for clinical take was the World Health Organization (WHO) [2] definition requiring a vesicular or postular lesion or an area of palpable induration surrounding a central lesion. An additional end point was the rate of vaccinia-specific serum antibody response.
Analysis of serum antibody response. For ELISAs, 96-well microtiter plates (MaxiSorp) were coated with 15 mg/mL bpropiolactone-inactivated crude vaccinia antigen (IHD-J strain; 50 mL/well) in NaHCO 3 buffer (50 mmol/L; pH 9.6). The plates were blocked with TSTA buffer (50 mmol/L Tris [pH 7.6], 142 mmol/L sodium chloride, 0.05% sodium azide, 0.05% Tween 20, and 2% bovine serum albumin). Serial 2-fold dilutions of the tested serum samples (100 mL) were incubated on the plates for 2 h at 37ЊC. The plates were developed with alkaline phosphatase-conjugated rabbit anti-human IgG, followed by pnitrophenyl phosphate as substrate (both from Sigma). Finally, absorbance was measured at 405 nm. The end point for the tested serum samples was defined as the highest dilution exhibiting an absorbance 12 SDs above a negative control (serum from unvaccinated control subjects diluted 1:50). Antibody titers were expressed as the reciprocal end-point dilution.
The validated ELISAs were performed by use of a robotic system (Tecan). Serum samples with antibody levels below the cutoff value were given an arbitrary titer of one-half of that value, to allow for calculation of geometric mean titers (GMTs). In this assay, the GMT of serum samples from unvaccinated individuals was 28.4 (95% confidence interval [CI], 26.4-30.6).
A validated plaque-reduction neutralization test (PRNT) was used for the determination of PRNT titers in a subgroup of the vaccinees. Heat-inactivated serum samples (30 min at 56ЊC) were diluted in modified Eagle medium (MEM; Biological Industries) supplemented with 2% heat-inactivated fetal bovine serum (FBS). Serial 2-fold dilutions (0.35 mL of each) were incubated for 60 min at 37ЊC in 7.5% CO 2 with 0.35 mL of vaccinia suspension (Lister strain) containing 10 3 pfu/mL. At the end of the incubation period, 0.2 mL of the virus/serum mixture was allowed to adsorb for 60 min at 37ЊC in 7.5% CO 2 , on a monolayer of Vero cells (ATCC-81) in 12-well plates. At the end of the adsorption period, the cells were overlayered with 0.4% Tragacant (Sigma) in MEM supplemented with 2% FBS and 2.4% NaHCO 3 . After an incubation period of 72 h, the medium was removed and the cells were fixed with 70% ethanol. The monolayer was stained with 0.3% basic fucsin in 10% ethanol and 5% buffered phenol. A 50% PRNT titer was determined by use of the Spear-Karber method for ED 50 [6] . In this assay, the GMT of serum samples from unvaccinated individuals was 8.9 (95% CI, 8.3-9.5). A reference standard, VIGIV Lot 1 (Center for Biologics Evaluation and Research, Food and Drug Administration), had titers of 42,224 by ELISA and 2955 by PRNT (manufacturer titer range for the VIGIV, 1000-2000 PRNT).
For the immunological analysis, a 4-fold increase in antibody titer between days 0 and 14 was considered to be seroconversion. Using these tests, correlation coefficient values of 0.39 (before vaccination) and 0.89 (after vaccination) were found between the log titers of ELISA and PRNT.
Statistical analysis. Differences in proportions of local and systemic reactions and immune response, in terms of clinical take and seroconversion after inoculation with the vaccinia vaccine, were determined by Fisher's exact test. Comparison of GMTs of vaccinia antibodies in the prevaccination and postvaccination serum samples were tested for statistical significance by the independent samples t test.
The Cochran-Armitage trend test was used to analyze changes in rates of clinical take or seroconversion. All statistical tests were 2-tailed.
was considered to be statistically significant. P ! .05
RESULTS
Clinical success rate and reactogenicity. The clinical success rate, as determined by the presence of a vesicle, pustule, ulcer, or scab on days 7-9 (the IMH criteria), was 60.8% (96/158). No differences in success rates were found between the female and male vaccinees. The rate of clinical take on days 3-4 after vaccination was 46.2% (72/156). Approximately one-third (27/ 83) of the vaccinees who were negative on days 3-4 developed full clinical take on days 7-9. Only 4 (5.6%) of the 72 vaccinees who were positive on days 3-4 were negative on days 7-9 (only 1 of these 4 seroconverted, by ELISA). Therefore, for analysis of clinical take, only data for days 7-9 were considered. When the WHO criteria for clinical take were applied, the success rate on days 7-9 was ∼49%. For all other analyses, unless stated otherwise, we used the IMH criteria for clinical take. Table 1 summarizes the local signs and symptoms identified in the vaccinees on days 7-9. There was a clear correlation between the rate of local reactions (other than those included in the definition of clinical take) and clinical take. Nevertheless, a significant number of vaccinees without clinical take reported the appearance of local signs. Five vaccinees with clinical take developed pustules in locations other than the primary vaccination site: 1 had a pustule on the shoulder, ipsilateral to the vaccinated arm; 1 had a pustule on the back of the neck; and 3 had pustules at a distance of 3-4 cm from the site of primary vaccination. Approximately 2 weeks after vaccination (days 14-18), 19.0% of the vaccinees reported pruritus, and 5.2% reported local pain. In comparison, 67.1% and 22.4% of the vaccinees reported pruritus and/or local pain, respectively, on days 7-9 ( ). Lymphodenopathy was predominantly fo-P ! .01 cused on the vaccinated arm. Table 2 summarizes the systemic signs and symptoms reported by the vaccinees and control subjects. Among the vaccinees, fatigue, headache, and muscle ache were the most common complains, with 29.1%, 19.7%, and 12.7% of the vaccinees, respectively, reporting at least 1 of these. The major symptoms that were associated with severe complaint (i.e., interfering with routine activity) were headache (5.7%) and fatigue (9.5%). Approximately 11% of the vaccinees and 15% of the control subjects reported at least 1 severe symptom during the first 7-9 days of follow-up (P p ). Fatigue was the only specific symptom that was signifi-.47 cantly higher in the vaccinees on days 7-9 days, compared with that in the control subjects (28.9% in the vaccinees vs. 12.5% in the control subjects [ ]). Approximately 2 weeks after P p .02 vaccination (days 14-18), fatigue in the vaccinees declined to 14.3%, which was very similar to that reported by the control subjects (P p .86). The signs and symptoms that were reported by the control subjects probably reflected the background rate of symptoms in the general population during the winter season in which the study took place. Most complaints that were re- ported under the Other category were also related to cold and flu-like symptoms.
The mean duration of symptoms in vaccinees ranged from 2.4 days (headache) to 4.8 days (pruritus). Pruritus was the only symptom that lasted significantly longer in vaccinees with clinical take than in those without clinical take (5.1 days and 3.8 days, respectively, [ ]). P ! .01 Antibody response and correlation with clinical findings. Serum samples from 159 vaccinees were analyzed by ELISA for the presence of vaccinia-specific antibodies (figure 1). When all serum samples from vaccinees on days 14-18 were analyzed, there was a 5-fold increase in the GMT, from 511 to 2547, of vacciniaspecific antibodies. The GMT decreased by ∼25%, from 2547 to 1926, 2 weeks later. The GMT of the vaccinees with clinical take increased ∼13-fold, from 372 to 4982 (figure 1), whereas the GMT of the vaccinees without clinical take was stable. No differences in antibody titers were found between the female and male vaccinees. The level of vaccinia-specific antibodies on day 0 in the group of vaccinees who eventually developed clinical take was significantly lower than that in the group who failed to develop clinical take (GMT, 372 vs. (table 3) . Additional parameters in this group pointed to a low response: 10 of the 11 were tested by PRNT, and 9 were found to be negative. Only 1 vaccinee in this group had erythema with a diameter 110 mm, compared with a mean diameter of 21.7 mm for all vaccinees with clinical take. Nine of the 11 had a scab as the sign of clinical take. Table 4 depicts the rate of seroconversion in groups of vaccinees with different types of local signs. The rate of seroconversion in the vaccinees with local responses who met the WHO criteria for clinical take was high (87%-95%). In the vaccinees with a scab only, the rate of seroconversion was low (∼67%). The rate of seroconversion in the vaccinees with signs of erythema or with induration/papule was very low (0%-17%).
It is worth noting that ∼20% (9 of 46) of the vaccinees with a scab plus induration/papule or with a scab only did not seroconvert by ELISA. In comparison, only 4.5% (2 of 44) of the vaccinees with a vesicle, postule, or ulcer did not seroconvert by ELISA; 1 of the 2 seroconverted by PRNT.
Another interesting group comprised 5 vaccinees who seroconverted by ELISA but did not show signs of clinical take on days 7-9. Of these, 4 seroconverted by PRNT as well. These vaccinees had a trend toward larger erythema (mean diameter, 10.8 mm), compared with that for all of the vaccinees without clinical take (mean diameter, 3.4 mm). Four of the 5 reported pruritus at the site of inoculation, compared with approximately one-third of all of the vaccinees without clinical take. Of the other 54 vaccinees without clinical take, 2 had a moderate increase in antibody titer (12 but !3-fold increase). The level of preexisting antibodies had a significant effect on the outcome response (clinical take or seroconversion) (figure 2). Of the vaccinees with preexisting antibody titers у1600, only 35% and 26% developed clinical take or seroconverted, respectively. In comparison, of the vaccinees with preexisting antibody titers !1600, 65% and 62% developed clinical take or seroconverted, respectively ( , for clinical take; P p .0098 P p , for seroconversion). PRNT substantiated these results .0024 (data not shown). Furthermore, of the vaccinees with low preexisting antibody titers (р200), 89% and 86% developed clinical take or seroconverted, respectively.
We evaluated the effect that time since last vaccination had on the success rates and serological parameters (table 5). The rates of clinical take and seroconversion were associated with the length of time since last vaccination. Nearly 40% of the most recently vaccinated vaccinees (!10 years) developed clinical take or seroconverted, whereas 74%-79% of the vaccinees last vaccinated 120 years before the current campaign developed clinical take or seroconverted ( , for clinical take; P p .001 , for seroconversion). The higher rates of response for P ! .0001 those vaccinees with 120 years since their last vaccination were associated with a trend toward lower preexisting antibody titers ( ) . P p .0173
DISCUSSION
The threat that variola virus could be used as a bioterror agent has raised the need to reevaluate the safety and immunogenicity of the current vaccines against smallpox in different populations. The decision to immunize a group of first responders in Israel provided an opportunity to analyze the clinical and serological response to the locally produced Lister strain of vaccinia vaccine in previously vaccinated individuals (most of them had been immunized 2-3 times before the current campaign). The vaccine had a high safety profile in the 159 vaccinees ex- amined. No serious adverse events were noted. The systemic signs and symptoms reported by the vaccinees were minor, with headache, muscle ache, and fatigue being the most frequent. The rates of symptoms were lower than those reported by naive vaccinees in a study in the United States [7] . A major limitation of the present study with regard to the safety analysis was the open design, which may affect the rates of the general symptoms and signs reported by the vaccinees. In addition, the study took place during the winter season, therefore increasing the chances of including unrelated flu-like symptoms as possible adverse reactions due to vaccination. The later was partially controlled by analyzing unvaccinated individuals. Indeed, we found that, with the exception of fatigue, there were no significant differences in the rates of systemic symptoms between vaccinees and control subjects.
With regard to the vaccination success rate, we chose to analyze the data by applying the criteria used in Israel for the locally produced vaccine and inoculation procedure. These criteria were then challenged with the criteria set by WHO. We found that 46% and 61% of the vaccinees showed a significant clinical response on days 3-4 and days 7-9, respectively, after vaccination. These data corroborate the findings of studies conducted in Israel during the 1960s revealing that children 9-10 years of age who were reimmunized by the same multipuncture technique had a 42% rate of clinical take on day 4 after vaccination and a 66% rate of clinical take on day 7 after vaccination [8] . Because local symptoms in the vaccinees indicate active infection, it is not surprising that the occurrence of local reactions in the vaccinees was correlated with positive clinical take. Nevertheless, a substantial proportion of the vaccinees who failed to develop full clinical take had significant local symptoms (for pruritus, ∼30%). This finding might indicate that some neutralizing activity occurred at the site of inoculation, as will be discussed later. The serum immune response was evaluated by direct ELISA, with b-propiolactone-inactivated vaccinia virus as an antigen. Studies conducted before the introduction of the ELISA method suggested that PRNT was more sensitive than other assays (such as the agglutinationinhibition assays) that were in use at that time to detect vaccinia-specific antibodies [9] . Later, Lublin-Tennenbaum et al. [10] compared clinical responses to PRNT and ELISA after revaccination. They showed a relatively weak correlation between the levels of vaccinia-specific antibodies as determined by PRNT and ELISA. However, 3 weeks after revaccination, a significant correlation was observed between the levels of vaccinia-specific antibodies as determined by the 2 assays. In a recent study, Frey et al. [11] showed that ELISA is ∼20% less sensitive than PRNT for the detection of vaccinees with clinical take. In the present study, we found that, in 32 pairs of serum samples tested by both ELISA and PRNT, 30 exhibited agreement with the definition of seroconversion (4-fold increase in antibody titer). Our use of ELISA appears to be justifiable, because 88% of the vaccinees with clinical take seroconverted by ELISA.
The antibody response in the group of vaccinees peaked on day 14, which was in accordance with what has been reported previously for revaccination [12, 13] . The group of vaccinees with clinical take but without seroconversion is of special interest. The definition for clinical take in this group was mostly determined by the presence of a scab at the site of inoculation. Approximately 20% of the vaccinees with a scab as the sign for clinical take did not seroconvert, compared with !5% of the vaccinees with a vesicle, postule, or ulcer. When the WHO criteria for clinical take were applied, the rate of vaccinees with clinical take but without seroconversion was lowered, but there was a trend toward a lower rate of agreement between clinical take and seroconversion. This result suggests that the WHO criteria might be more sensitive and useful for advising individual vaccinees on whether to get an additional inoculation, whereas the criteria used by the IMH might better reflect the immunological status of the vaccinated population.
Previous studies, both ones that were conducted recently as well as others that date to the eradication campaign, have suggested that immunity elicited by vaccinia may persist, at least partly, for decades and is responsible for neutralizing activity against vaccinia virus [12, [14] [15] [16] [17] [18] . During the 1960s, Nyerges et al. [16] showed that the rate of clinical take is correlated with the age of the vaccinees, suggesting that time since last vaccination is a crucial factor. Neff et al. [15] demonstrated the relationships between levels of preexisting antibodies and rates of clinical take or seroconversion. The data from the present study strongly support the former observations and the idea that residual immune response in vaccinees, even 120 years after receiving the vaccine, might be responsible for the presumed neutralization activity against vaccinia virus. We have shown that the level of preexisting antibodies is associated with time since last immunization and that the rate of clinical response might range between 35% and 89%, depending on the level of preexisting antibodies. Our results with vaccinees last immunized 120 years before the current campaign were similar to the ones achieved by Frey et al., who used a 1:10 dilution of the US vaccine for revaccination of individuals 30 years after they had received the previous inoculation [12] . The 1:10 dilution of the US vaccine is acceptable for immunization of naive individuals and for revaccination [12] . Interestingly, the vaccinees in the present study with very low preexisting antibody titers (р200) had a rate of clinical take of ∼90%, which was very similar to the rate demonstrated in naive individuals during the eradication campaign and in recent studies [7] . We have shown that a significant number of the vaccinees who did not respond to revaccination had relatively high levels of preexisting antibodies. This finding strongly supports the idea that a significant portion of the nonresponding vaccinees were already immune to smallpox before receiving the vaccine.
Unsuccessful immunization can be attributed to a technical failure related to vaccine administration, an efficient neutralization of the vaccine strain by a vaccinee's immune system, or a host factor that limits the immune response. The findings of the present study indicate that, in general, technical failure related to vaccine administration likely is not a factor. We cannot preclude, however, that a higher dose, a more potent vaccine, or a more efficient administration technique could lead to higher response rates. The data presented here indicate that, in revaccinated individuals, the vaccine preparations being used in Israel (the Lister strain of vaccinia virus) produce the expected safety profile and clinical responses, which are similar to those achieved during the eradication campaign. However, more studies are needed to characterize the populations not responding to the vaccine, as well as to evaluate the performance of the vaccine in naive individuals. 
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